2026 Deceptive Ad Trends
A closer look at what we’ll be monitoring in the new year.
Ozempic, Wegovy, and Other GLP-1 RA Medications
Multiple class-action lawsuits regarding the marketing of GLP-1 RAs were transferred to be heard together as part of multidistrict litigation (MDL). More information on the MDL is below.
Case Name (Date)
In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
24-md-3094, E.D. Penn.
(2024)
Product/Service
Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, Mounjaro, Zepbound, Trulicity and other GLP-1 RA medications
Allegations
Marketing products as weight-loss medications without adequately disclosing that many people stop using them due to their side effects, the medications do not result in meaningful weight loss for up to 15 percent of people, the average weight loss is approximately 10 percent of a person’s body weight, and people need to stay on them to maintain their weight loss
Status
Pending
The Latest
Why ‘Click-to-Cancel’ Still Matters – and Why the FTC Should Try Again
The problem hasn’t gone away.
Amazon’s Great Holiday Climb
Why parents may need to be called in to this Roblox game rated 13+.
Interior Icons’ 10-Year Warranty and 365-Day Returns
Taking advantage of these perks may be harder than advertised.
TINA.org’s Year in Review 2025
Looking back at our accomplishments